Supplementary Figure 1. Details of the trial schedule

			Clinical trial period							Clinical trial period (continuous trial)				
Item		Pre-evaluation period			Evaluation period				Continuous-evaluation period					Follow-up period
		2 weeks before intervention	1st day		2nd day	3rd day	4th day	5th day or abortion		1st week	2nd week	3rd week	4th week	4 weeks after completion of intervention
Informed consent		+												
Eligibility evaluation (VAS, MMSE, BDI-II)		+												
Final eligibility test (Compliance test)			+											
Definitive registration and assignment			+											
Eligibility evaluation for continuous trial									+					
Informed consent for continuous trial									+					
Intervention	Active or sham stimulation			+	+	+	+	+						
	Active stimulation									+	+	+	+	
VAS	Immediately before intervention			+	+	+	+	+		+	+	+	+	
	Immediately after intervention			+	+	+	+	+		+	+	+	+	
SF-MPQ2	Immediately before intervention			+	+	+	+	+		+	+	+	+	
	Immediately after intervention			+	+	+	+	+		+	+	+	+	
PGIC ^a	After intervention							+					+b	
BDI-II ^a , EQ-5D-5L ^a				+°				+ ^d					+e	
Final evaluation (VAS, SF-MPQ2, MMSE, BDI-II)														+
Adverse events and malfunction of devices				+	+	+	+	+		+	+	+	+	+
Evaluation of blindness ^a After intervention				+				+						

The schedule of evaluations is shown. Evaluations during the continuous trial were performed on the day of the intervention (at least once weekly).

Abbreviations: VAS, visual analogue scale; MMSE, Mini mental state examination; BDI-II, Beck Depression Inventory second version; SF-MPQ2, short-form McGill pain questionnaire 2; PGIC, Patient Global Impression of Change; EQ-5D-5L, European Quality of Life-5 Dimensions 5-level.

^a Performed on the day of treatment termination or the day after treatment termination in cases of study withdrawal.

^b Evaluated on the final day of intervention. ^c Evaluated before the intervention.

^d Evaluated after the intervention. ^e Evaluated after the final intervention.